Table 1 Baseline characteristics and mortality at follow-up of ADPKD patients stratified by RRT status

N

6142

1452 (23.6)

4690 (76.4)

Sex

 < .001

 Male

3169 (51.6)

806 (55.5)

2363 (50.4)

 Female

2973 (48.4)

646 (44.5)

2327 (49.6)

Age

 < .001

 20—39

1617 (26.3)

166 (11.4)

1451 (30.9)

 40—59

2752 (44.8)

731 (50.3)

2021 (43.1)

  ≥ 60

1773 (28.9)

555 (38.2)

1218 (26.0)

Age (years) at initiation of RRT

-

59.2 ± 13.4

58 (39, 82)

-

Comorbidities

 Hypertension (HTN)

3951 (64.3)

1245 (85.7)

2706 (57.7)

 < .001

 Dyslipidemia (DLP)

1476 (24.0)

417 (28.7)

1059 (22.6)

 < .001

 Diabetes Mellitus (DM)

786 (12.8)

252 (17.4)

534 (11.4)

 < .001

Combinations of HTN, DLP, and DM

 < .001

 HTN ( +) DLP (-) DM (-)

2372 (38.6)

737 (50.8)

1635 (34.9)

 HTN (-) DLP ( +) DM (-)

143 (2.33)

9 (0.62)

134 (2.86)

 HTN (-) DLP (-) DM ( +)

65 (1.06)

15 (1.03)

50 (1.07)

 HTN ( +) DLP ( +) DM (-)

891 (14.5)

274 (18.9)

617 (13.2)

 HTN ( +) DLP (-) DM ( +)

279 (4.54)

103 (7.09)

176 (3.75)

 HTN (-) DLP ( +) DM ( +)

33 (0.54)

3 (0.21)

30 (0.64)

 HTN ( +) DLP ( +) DM ( +)

409 (6.66)

131 (9.02)

278 (5.93)

 HTN (-) DLP (-) DM (-)

1950 (31.8)

180 (12.4)

1770 (37.7)

Drug History

 Metformin

70 (1.14)

11 (0.76)

59 (1.26)

0.117

 NSAIDs

373 (6.07)

48 (3.31)

325 (6.93)

 < .001

Duration of follow-up (months)

 From ADPKD diagnosis to RRT or censor date^a

73.82 ± 54.02

64.69 (3.32, 171.99)

40.94 ± 40.59

26.84 (0.99, 129.58)

84.00 ± 53.60

79.41 (6.74, 176.18)

 < .001

 From ADPKD diagnosis to death

or censor date^a

77.97 ± 52.73

71.47 (5.22, 173.0)

91.85 ± 52.11

89.54 (12.04, 180.5)

73.67 ± 52.18

65.38 (4.14, 169.5)

 < .001

 From RRT to death or censor date^a

-

50.91 ± 44.45

39.70 (1.08, 138.1)

-

Death

1315 (21.4)

609 (41.9)

706 (15.1)

 Mortality Rate^b

2.33

3.59

1.79